Press Room

JDRF Lends Research Expertise to Danish Diabetes Academy

New York, NY, September 26, 2012 - JDRF announced today that it will partner with the Novo Nordisk Foundation to provide funding and training for the newly-established Danish Diabetes Academy (DDA). The academy, the first of its kind in Denmark, will employ as many as 300 staff with a goal of improving ...


JDRF Applauds FDA''s Approval of Lucentis to Treat Diabetic Macular Edema

JDRF is pleased by the U.S. Food and Drug Administration's (FDA) announcement today that it has approved the drug Lucentis (ranibizumab injection) for the treatment of diabetic macular edema (DME)-a major complication of diabetes and a leading cause of significant vision loss and blindness in adults....


JDRF collaborates to fill gaps in encapsulation research for type 1 diabetes

Recently, JDRF announced that it is jointly funding research at the Diabetes Research Institute (DRI) with The Leona M. and Harry B. Helmsley Charitable Trust. The grant will support the efforts of Dr. Camillo Ricordi and his team as they work to advance the field of islet cell implantation and encapsulation....


JDRF-Helmsley Charitable Trust to Fund Islet Encapsulation Research at Diabetes Research Institute

New York, NY, August 16, 2012 - JDRF, in collaboration with The Leona M. and Harry B. Helmsley Charitable Trust (HCT), announced today that it has finalized a grant in the area of islet cell encapsulation to Dr. Camillo Ricordi, M.D. and a team of investigators at the Diabetes Research Institute (DRI), ...


Study Aims to Increase Adoption of Advanced Diabetes Technology in Young People with Type 1 Diabetes

Markham, ON (April 27, 2012) – JDRF Canadian Clinical Trial Network (JDRF CCTN) is pleased to announce the launch of the Markham site of the first multi-centre pediatric study in Canada using insulin pump therapy and continuous glucose monitoring (CGM). The Markham site will be led by Dr. Susan ...


Human study re-ignites debate over controversial diabetes "cure"

NEW YORK, Aug 8 (Reuters) - A controversial experimental cure for type 1 diabetes, using a tuberculosis vaccine invented a century ago, appears to temporarily vanquish the disease, according to a study in a handful of patients led by a scientist long criticized by her peers.


JDRF-Funded Researchers from Two Universities Separately Discover the Links between Cell Stress, Inflammation, and Beta Cell Death in Diabetes

New York, NY, August 7, 2012--When JDRF-funded research teams from two separate universities met three years ago, they learned that they were on similar paths in their attempt to discover the link connecting beta cell stress with inflammation and beta cell death in type 1 diabetes (T1D). Rather than ...


JDRF-Funded Researchers Launch Study of New Drug's Ability to Improve Islet Cell Transplants

New York, NY, July 26, 2012--After islet cell transplantation, a patient with type 1 diabetes (T1D) often loses insulin independence over time due to the loss of islet cells, which occurs for a number of reasons including cell stress from the transplantation process. To address this major hurdle in ...


T1D Rise Among Youth Highlights the Importance of Renewed Research Funding

In June, the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH) released results from their latest SEARCH for Diabetes in Youth study. The data revealed a 23 percent growth in type 1 diabetes (T1D) prevalence, between 2001 and 2009, in Americans under age 20. ...


JDRF Youth Ambassador Carries Torch Before 2012 Olympic Games in London

New York, NY, July 27, 2012 - JDRF is excited to have taken part in one of the most celebrated traditions in sports this morning. 13-year old Cara Dartnell-Steinberg of London carried the Olympic torch only hours before it arrives at tonight's opening ceremony of the 2012 Summer Olympic Games. Cara ...


Lets turn type one into type none